Cargando…
MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention
BACKGROUND: People living with dementia in care homes frequently exhibit “behaviour that challenges”. Anti-psychotics are used to treat such behaviour, but are associated with significant morbidity. This study researched the feasibility of conducting a trial of a full clinical medication review for...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053151/ https://www.ncbi.nlm.nih.gov/pubmed/32122341 http://dx.doi.org/10.1186/s12913-020-5014-0 |
_version_ | 1783502985333047296 |
---|---|
author | Maidment, Ian D. Barton, Garry Campbell, Niyah Shaw, Rachel Seare, Nichola Fox, Chris Iliffe, Steve Randle, Emma Hilton, Andrea Brown, Graeme Barnes, Nigel Wilcock, Jane Gillespie, Sarah Damery, Sarah |
author_facet | Maidment, Ian D. Barton, Garry Campbell, Niyah Shaw, Rachel Seare, Nichola Fox, Chris Iliffe, Steve Randle, Emma Hilton, Andrea Brown, Graeme Barnes, Nigel Wilcock, Jane Gillespie, Sarah Damery, Sarah |
author_sort | Maidment, Ian D. |
collection | PubMed |
description | BACKGROUND: People living with dementia in care homes frequently exhibit “behaviour that challenges”. Anti-psychotics are used to treat such behaviour, but are associated with significant morbidity. This study researched the feasibility of conducting a trial of a full clinical medication review for care home residents with behaviour that challenges, combined with staff training. This paper focusses on the feasibility of measuring clinical outcomes and intervention costs. METHODS: People living with moderate to severe dementia, receiving psychotropics for behaviour that challenges, in care homes were recruited for a medication review by a specialist pharmacist. Care home and primary care staff received training on the management of challenging behaviour. Data were collected at 8 weeks, and 3 and 6 months. Measures were Neuropsychiatric Inventory-Nursing Home version (NPI-NH), cognition (sMMSE), quality of life (EQ-5D-5 L/DEMQoL) and costs (Client Services Receipt Inventory). Response rates, for clinical, quality of life and health economic measures, including the levels of resource-use associated with the medication review and other non-intervention costs were calculated. RESULTS: Twenty-nine of 34 participants recruited received a medication review. It was feasible to measure the effects of the complex intervention on the management of behaviour that challenges with the NPI-NH. There was valid NPI-NH data at each time point (response rate = 100%). The sMMSE response rate was 18.2%. Levels of resource-use associated with the medication review were estimated for all 29 participants who received a medication review. Good response levels were achieved for other non-intervention costs (100% completion rate), and the EQ-5D-5 L and DEMQoL (≥88% at each of the time points where data was collected). CONCLUSIONS: It is feasible to measure the clinical and cost effectiveness of a complex intervention for behaviour that challenges using the NPI-NH and quality of life measures. TRIAL REGISTRATION: ISRCTN58330068. Retrospectively registered, 15 October 2017. |
format | Online Article Text |
id | pubmed-7053151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70531512020-03-10 MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention Maidment, Ian D. Barton, Garry Campbell, Niyah Shaw, Rachel Seare, Nichola Fox, Chris Iliffe, Steve Randle, Emma Hilton, Andrea Brown, Graeme Barnes, Nigel Wilcock, Jane Gillespie, Sarah Damery, Sarah BMC Health Serv Res Research Article BACKGROUND: People living with dementia in care homes frequently exhibit “behaviour that challenges”. Anti-psychotics are used to treat such behaviour, but are associated with significant morbidity. This study researched the feasibility of conducting a trial of a full clinical medication review for care home residents with behaviour that challenges, combined with staff training. This paper focusses on the feasibility of measuring clinical outcomes and intervention costs. METHODS: People living with moderate to severe dementia, receiving psychotropics for behaviour that challenges, in care homes were recruited for a medication review by a specialist pharmacist. Care home and primary care staff received training on the management of challenging behaviour. Data were collected at 8 weeks, and 3 and 6 months. Measures were Neuropsychiatric Inventory-Nursing Home version (NPI-NH), cognition (sMMSE), quality of life (EQ-5D-5 L/DEMQoL) and costs (Client Services Receipt Inventory). Response rates, for clinical, quality of life and health economic measures, including the levels of resource-use associated with the medication review and other non-intervention costs were calculated. RESULTS: Twenty-nine of 34 participants recruited received a medication review. It was feasible to measure the effects of the complex intervention on the management of behaviour that challenges with the NPI-NH. There was valid NPI-NH data at each time point (response rate = 100%). The sMMSE response rate was 18.2%. Levels of resource-use associated with the medication review were estimated for all 29 participants who received a medication review. Good response levels were achieved for other non-intervention costs (100% completion rate), and the EQ-5D-5 L and DEMQoL (≥88% at each of the time points where data was collected). CONCLUSIONS: It is feasible to measure the clinical and cost effectiveness of a complex intervention for behaviour that challenges using the NPI-NH and quality of life measures. TRIAL REGISTRATION: ISRCTN58330068. Retrospectively registered, 15 October 2017. BioMed Central 2020-03-02 /pmc/articles/PMC7053151/ /pubmed/32122341 http://dx.doi.org/10.1186/s12913-020-5014-0 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Maidment, Ian D. Barton, Garry Campbell, Niyah Shaw, Rachel Seare, Nichola Fox, Chris Iliffe, Steve Randle, Emma Hilton, Andrea Brown, Graeme Barnes, Nigel Wilcock, Jane Gillespie, Sarah Damery, Sarah MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention |
title | MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention |
title_full | MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention |
title_fullStr | MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention |
title_full_unstemmed | MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention |
title_short | MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention |
title_sort | medrev (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053151/ https://www.ncbi.nlm.nih.gov/pubmed/32122341 http://dx.doi.org/10.1186/s12913-020-5014-0 |
work_keys_str_mv | AT maidmentiand medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT bartongarry medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT campbellniyah medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT shawrachel medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT searenichola medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT foxchris medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT iliffesteve medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT randleemma medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT hiltonandrea medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT browngraeme medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT barnesnigel medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT wilcockjane medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT gillespiesarah medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention AT damerysarah medrevpharmacyhealthpsychologyinterventioninpeoplelivingwithdementiawithbehaviourthatchallengesthefeasibilityofmeasuringclinicaloutcomesandcostsoftheintervention |